Janssen Research & Development, Llc

This study compares two versions of the drug teclistamab—one made with the current process and one with a new process—in 108 people with multiple myeloma that has come back or not responded to treatment. The main goal is to see if the body absorbs and handles both versions the sa…

This phase 3 study tests an oral drug called JNJ-77242113 in 311 adults with plaque psoriasis affecting special areas like the scalp, genitals, or palms and soles. Participants receive either the drug or a placebo for 16 weeks. The main goal is to see if the drug clears or nearly…

This phase 3 trial tests an oral drug called JNJ-77242113 in 774 adults with moderate to severe plaque psoriasis. Participants receive either the new drug, a placebo, or an active comparator (deucravacitinib) to see how well it clears skin lesions. The main goal is to measure imp…

This phase 3 trial tests whether a one-time infusion of cilta-cel, a CAR-T cell therapy, works better than standard drug combinations (PVd or DPd) for people with multiple myeloma that has come back and no longer responds to lenalidomide. About 419 participants will be randomly a…

This phase 3 study tests an experimental oral drug, JNJ-77242113, in about 731 adults with moderate to severe plaque psoriasis. Participants receive either the new drug, a placebo, or an active comparator (deucravacitinib) to see how well it clears skin lesions. The main goal is …

This phase 3 study tests whether adding the targeted drug amivantamab to standard chemotherapy helps people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). About 308 participants will receive either the combination or chemotherapy a…

This phase 3 trial tests an oral drug called JNJ-77242113 for people with moderate to severe plaque psoriasis. About 684 participants will receive either the drug or a placebo to see if it improves skin clearance. The study also includes a withdrawal and retreatment phase to chec…

This phase 3 trial compares a combination of two targeted drugs, amivantamab and lazertinib, against the standard drug osimertinib as a first treatment for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). About 1,074 participants will…

This study tests whether adding the experimental drug talquetamab to standard treatments (daratumumab and pomalidomide) helps people with multiple myeloma that has returned or stopped responding to prior therapy. About 864 adults will receive either the new combination or the usu…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This study tests an injected drug called guselkumab for people with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. About 418 adults who haven't responded well to other treatments will receive either the…

This study tests a drug called golimumab in children aged 2-17 with moderate-to-severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. The goal is to see if the drug can bring about remission (symptom relief) within 6 week…

This study tests a targeted pill (erdafitinib) against standard chemotherapy or immunotherapy in people with advanced bladder cancer that has specific FGFR gene changes. About 629 participants whose cancer worsened after prior treatments will be randomly assigned to receive erdaf…

This phase 2 trial is testing several drug combinations—including niraparib, cetrelimab, abiraterone acetate, and prednisone—in 136 men with metastatic castration-resistant prostate cancer (mCRPC), a form of the disease that has spread and stopped responding to standard hormone t…

This study tests whether combining two biologic drugs, guselkumab and golimumab, works better than either drug alone for people with moderate to severe ulcerative colitis. About 577 participants who haven't responded well to other advanced therapies will receive injections of the…

This phase 2b study tests whether combining two biologic drugs, guselkumab and golimumab, works better than either drug alone for people with moderate to severe Crohn's disease. About 703 participants will receive the combination or a placebo over 48 weeks. The goal is to see if …

This large study tests whether guselkumab, an injected drug, can control symptoms and heal the gut lining in people with moderate to severe Crohn's disease. About 1,400 participants will receive guselkumab, an existing treatment (ustekinumab), or a placebo. The goal is to see if …

This study tests a drug called guselkumab in children aged 6 to 17 with chronic plaque psoriasis. The goal is to see if it safely clears skin patches better than a placebo or another treatment. About 120 participants will receive injections and be monitored for 16 weeks.

This study tests a drug called teclistamab in people with multiple myeloma that has come back or stopped responding to treatment. The drug is a special antibody that helps the body's immune cells find and attack cancer cells. About 194 participants will receive the drug to see ho…

This study tests a new form of the drug amivantamab that can be given as a shot under the skin, combined with the pill lazertinib, for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has worsened after prior treatments. The goal …

This phase 3 study tests whether a combination of two targeted drugs, ibrutinib and venetoclax, works better than the current standard therapy (chlorambucil plus obinutuzumab) for adults with chronic lymphocytic leukemia (CLL) who have not yet been treated. The main goal is to se…

This phase 3 trial tests whether adding two targeted drugs (amivantamab and lazertinib) to standard chemotherapy can help people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) whose cancer has stopped responding to the drug osimertinib. Abo…

This early-phase study tests a new drug (JNJ-87801493) combined with immune-activating therapies (T-cell engagers) in about 70 people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to other treatments. The main goals are to check safety and find the best dos…

This phase 3 trial tests a new approach for people with muscle-invasive bladder cancer who cannot or choose not to have their bladder removed. Participants receive either a combination of TAR-200 (a drug placed directly into the bladder) plus cetrelimab (an immunotherapy), or sta…

This early-phase trial is testing a new treatment called JNJ-90009530, a type of CAR-T cell therapy that targets a protein called CD20 on lymphoma cells. The study includes 21 adults with relapsed or refractory B-cell non-Hodgkin lymphoma who have already tried other treatments. …

This early-stage trial tests combinations of the drug daratumumab with two newer bispecific antibodies (talquetamab and teclistamab), with or without pomalidomide, in 290 people with multiple myeloma. The main goal is to find safe doses and understand side effects. Participants m…

This study tests whether adding apalutamide to standard hormone therapy before and after prostate removal surgery can improve outcomes for men with high-risk prostate cancer. About 2,500 participants will receive either the drug combination or a placebo. The goal is to see if the…

This study tests a new treatment called TAR-200 for people with a high-risk type of bladder cancer that came back after standard therapy (BCG). Participants either receive TAR-200 or standard chemotherapy placed directly into the bladder. The goal is to see if TAR-200 can keep th…

This study looks at how the body absorbs different versions of two prostate cancer drugs, niraparib and abiraterone acetate, taken together with prednisone. It involves 136 men with metastatic castration-resistant prostate cancer. The goal is to compare the absorption of various …

This early-phase study tests a new drug, JNJ-87562761, in 17 people with multiple myeloma whose cancer returned or didn't respond to prior treatments. The main goals are to find a safe dose and check for side effects. Participants must have measurable disease and have tried certa…

This early-stage study tests the drug apalutamide in 19 Chinese men whose prostate cancer has spread and no longer responds to hormone therapy. Researchers want to see how the drug behaves in the body and if it is safe. They will also check if it lowers PSA levels, a marker of ca…

This phase 3 trial tests whether adding the drug niraparib to standard treatment (abiraterone and prednisone) can slow the growth of metastatic prostate cancer that no longer responds to hormone therapy. About 765 men with specific genetic changes are taking part. The study compa…

This study tests a combination of two drugs, amivantamab and cetrelimab, in people with advanced non-small cell lung cancer that has spread. The goal is to find the safest dose and see if the combo can shrink tumors. About 71 participants will take part in this early-stage trial.

This study tests an experimental drug called M281 (Nipocalimab) in adults with warm autoimmune hemolytic anemia, a condition where the immune system attacks red blood cells. The trial compares M281 to a placebo to see if it can improve hemoglobin levels and reduce fatigue. About …

This phase 3 study tests guselkumab (Tremfya) in 453 adults with active psoriatic arthritis who did not respond to or could not tolerate a prior anti-TNF drug. Participants receive either guselkumab or a placebo injection. The main goal is to see if guselkumab reduces joint swell…

This early-phase study is testing a combination of two treatments—cilta-cel (a cell therapy) and talquetamab (a drug)—in 11 people with high-risk multiple myeloma that has not responded to prior therapies. The main goal is to check safety and side effects. Researchers will also l…

This study tests guselkumab, a drug that targets inflammation, in over 1,000 people with moderate to severe ulcerative colitis. Participants receive either guselkumab or a placebo to see if the drug can improve symptoms and lead to remission. The goal is to find a new treatment o…

This phase 3 trial tested guselkumab, a biologic drug given as a shot, in over 1,000 people with active psoriatic arthritis who had not responded well to other treatments. The goal was to see if it reduces symptoms like joint pain and swelling and slows joint damage seen on X-ray…

This study looks at whether special skin care can lower the chance of bad skin reactions in people with advanced lung cancer who are taking a combination of two drugs (amivantamab and lazertinib). About 305 participants will be randomly assigned to standard skin care or enhanced …

This early-stage study tests a new oral drug, JNJ-88998377, in about 58 people with relapsed or refractory B-cell non-Hodgkin's lymphoma (a type of blood cancer). The main goals are to check the drug's safety and find the best dose for future studies. Participants must have measu…

This early-stage trial tests a new drug called talquetamab in 279 people with multiple myeloma that has come back or stopped responding to other treatments. Talquetamab is a bispecific antibody designed to help the immune system attack cancer cells. The main goals are to check sa…

This early-phase study tests a new drug, JNJ-69086420, that delivers a radioactive particle directly to prostate cancer cells. The trial involves about 144 men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The main goals ar…

This study is a follow-up to a Phase 3 trial testing a gene therapy called AAV5-hRKp.RPGR for people with X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss. The treatment aims to slow or stop vision decline by delivering a working copy of the RPGR gene …

This early-stage trial tests a new drug called amivantamab in people with advanced non-small cell lung cancer. The drug is a special antibody that targets two proteins on cancer cells. Researchers are checking safety and how well it works, both alone and with other treatments. Ab…

This study tests whether the drug apalutamide can delay prostate cancer progression in Chinese men whose cancer has stopped responding to standard hormone therapy but hasn't spread to other parts of the body. About 75 participants will receive either apalutamide or a placebo, alo…

This study tests two experimental treatments—TAR-200 (a drug placed inside the bladder) and cetrelimab (an immunotherapy injection)—alone or together, in people with high-risk bladder cancer that came back after BCG therapy. Participants are those who cannot or choose not to have…

This large Phase 3 study tests whether milvexian, an experimental oral blood thinner, can prevent another stroke in people who recently had a mild stroke or a high-risk mini-stroke (TIA). Over 12,500 participants are randomly assigned to receive either milvexian or a placebo, alo…

This early-stage study tests a new drug called teclistamab in people with multiple myeloma that has returned or stopped responding to other treatments. The main goal is to find a safe dose and check for side effects. About 300 participants will receive the drug to see how well it…

This phase 3 trial tests two new approaches for high-risk bladder cancer that hasn't spread into the muscle. One group gets a drug called TAR-200 placed directly into the bladder plus an immunotherapy drug (cetrelimab). Another group gets TAR-200 alone. These are compared to the …

This early-stage study tests a new drug called teclistamab combined with other cancer treatments for people with multiple myeloma, a type of blood cancer. The main goal is to check safety and find the best doses. About 140 participants who have already tried other treatments will…

This Phase 3 trial tests if men with metastatic prostate cancer who respond well to initial treatment with apalutamide and hormone therapy can safely pause the hormone therapy to reduce hot flashes. About 420 participants will be randomly assigned to continue or pause hormone the…

This study tests whether guselkumab, given as a shot under the skin, can help people with moderate to severe Crohn's disease achieve remission and heal their gut lining. About 350 adults who have not responded well to other treatments will receive either guselkumab or a placebo. …

This Phase 3 trial tests an oral drug called JNJ-77242113 in 752 adults with moderate to severe plaque psoriasis. Participants receive either the new drug, a placebo, or an active comparator (Stelara). The study measures how well the drug clears skin lesions at 16 weeks. The goal…

This phase 3 trial is testing whether adding the drug niraparib to standard therapy (abiraterone and prednisone) can slow cancer growth in men with metastatic castration-sensitive prostate cancer who have specific inherited or tumor gene mutations. About 700 participants are bein…

This phase 3 trial compares a new CAR-T cell therapy (cilta-cel) plus standard drugs against standard drugs alone for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. About 743 participants will receive either the CAR-T combination or standard …

This early-phase study tests the safety of talquetamab combined with other cancer drugs in 166 people with multiple myeloma, a type of blood cancer. The goal is to find safe doses and check for side effects. Participants must have measurable disease and meet specific lab criteria…

This phase 4 trial tests whether guselkumab (TREMFYA) can reduce spine-related symptoms in people with active psoriatic arthritis who have not used biologic drugs before. About 411 participants will receive either guselkumab or a placebo as a shot under the skin. The main goal is…

This phase 3 trial tests whether nipocalimab can safely reduce disease activity in adults with moderate to severe Sjogren's disease. About 655 participants receive either nipocalimab or a placebo, along with standard care, for 48 weeks. The main goal is to see if the drug improve…

This study compares a new oral blood thinner, milvexian, to the standard apixaban in about 20,000 adults with atrial fibrillation (an irregular heartbeat). The goal is to see if milvexian is at least as good at preventing strokes and blood clots, while also checking for major ble…

This early-stage trial tests a new drug called JNJ-89853413 in 64 people whose acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS) have come back or stopped responding to treatment. The main goal is to check safety and find the right dose, with a second part looking a…

This study tests a combination of two drugs, amivantamab and capmatinib, in people with advanced non-small cell lung cancer that has spread. The goal is to find the best dose and see if the combination shrinks tumors. About 57 participants will be enrolled, and the study is curre…

This study tests an experimental drug called JNJ-77242113 (icotrokinra) against a placebo in 552 adults with active psoriatic arthritis who have not tried biologic treatments before. The main goal is to see if the drug reduces joint swelling and tenderness after 16 weeks. Partici…

This phase 2 trial tests a drug called erdafitinib in 239 people with advanced bladder cancer that has certain FGFR gene changes. The drug aims to shrink tumors by blocking signals that help cancer grow. Researchers are checking how well it works and what side effects occur.

This early-stage trial tests a new drug called ARX517, which is designed to find and kill prostate cancer cells while sparing healthy ones. It is being tested alone or with other standard treatments in 183 men with prostate cancer that has spread to other parts of the body. The m…

This study tests a gene therapy called botaretigene sparoparvovec in the second eye of people with X-linked retinitis pigmentosa, a genetic condition that causes vision loss. The 24 participants previously received the therapy in one eye and are now being followed for safety and …

This study follows 159 children aged 2 to 17 who have already completed a prior ustekinumab study for Crohn's disease, ulcerative colitis, or psoriatic arthritis. The goal is to collect long-term safety data by monitoring side effects, lab results, and injection-site reactions. P…

This phase 2 trial tests a drug combination including daratumumab for people with AL amyloidosis, a rare disease where abnormal proteins damage organs, especially the heart. The study has two groups: one gets the full combo right away, the other starts some drugs later. Researche…

This study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …

This early-stage study tests a new drug, JNJ-78278343, that helps the body's immune T-cells find and attack prostate cancer cells. It involves 216 men with advanced prostate cancer that has spread. The main goals are to find the safest and most effective dose and to monitor side …

This study is testing a new treatment called JNJ-68284528, a CAR-T cell therapy, for people with multiple myeloma. The goal is to see if it can reduce cancer cells to undetectable levels (called minimal residual disease negative). About 210 participants who have already tried oth…

This study tests a drug called guselkumab in children aged 2-17 with moderate to severe ulcerative colitis, a condition causing inflammation in the colon. The goal is to see if the drug can bring the disease under control and keep it in remission for up to 56 weeks. About 112 chi…

This early-phase study tests a new drug called JNJ-80948543 in people with non-Hodgkin lymphoma or chronic lymphocytic leukemia whose cancer has returned or not responded to other treatments. The drug works by redirecting the body's T-cells to attack cancer cells. The main goals …

This early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…

This study is for people newly diagnosed with a standard-risk form of multiple myeloma, a blood cancer. Researchers want to see if giving a sequence of advanced cell therapies (Cilta-cel, Tal-D, Tec-D) after initial chemotherapy can lead to a very deep and lasting remission, poss…

This early-stage study tests whether combining two types of immune-boosting drugs (bispecific antibodies and a checkpoint inhibitor) is safe for people with multiple myeloma that has come back or stopped responding to treatment. About 74 participants will receive either talquetam…

This early-phase trial tests two experimental drugs, JNJ-80948543 and JNJ-75348780, given together to people with relapsed or refractory B-cell non-Hodgkin lymphoma. The study involves 19 participants and aims to find the safest dose and check for side effects. It is not yet know…

This study is testing two injectable drugs, ustekinumab and guselkumab, in 50 children with active juvenile psoriatic arthritis. The goal is to see how well the drugs work, how they move through the body, and if they are safe. Participants will receive one of the drugs and be mon…

This early-stage study tests a new drug called bleximenib combined with other leukemia treatments for people with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A or NPM1). The main goals are to find the best dose and check for side effects. About 196 partici…

This phase 2 trial tests whether nipocalimab, given intravenously, can improve symptoms of active idiopathic inflammatory myopathies (myositis) better than a placebo. About 36 adults with myositis will receive either nipocalimab or a placebo, along with standard steroid treatment…

This study tests whether a new two-drug combination (teclistamab plus daratumumab) works better than standard three-drug combos for people whose multiple myeloma has returned or stopped responding to treatment. About 587 adults with measurable disease will be randomly assigned to…

This early-phase trial is testing two experimental drugs, lazertinib and amivantamab, alone or together, in 701 people with advanced non-small cell lung cancer. The goal is to find safe doses and see if the combination can shrink tumors. Participants have already tried standard t…

This program gives patients with high-risk non-muscle invasive bladder cancer access to TAR-200 before it is officially approved. TAR-200 is a device placed into the bladder that releases medication over time. It is for patients who have tried all other treatments and cannot join…

This study compares teclistamab (a newer immunotherapy) with two standard drug combinations (PVd or Kd) in about 614 adults whose multiple myeloma has come back or stopped responding after 1 to 3 prior treatments. The main goal is to see if teclistamab helps people live longer wi…

This study tests a targeted cancer drug called erdafitinib, alone or combined with an immunotherapy (cetrelimab) and/or chemotherapy, in 125 people with advanced urothelial cancer that has spread. The goal is to find safe doses and see if the treatments shrink tumors. Participant…

This was a planned phase 2 study testing nipocalimab, an experimental drug, in adults with active lupus nephritis (kidney inflammation caused by lupus). The trial aimed to see if adding nipocalimab to standard treatment could improve kidney function. However, the study was withdr…

This study tests a combination of two experimental drugs, talquetamab and teclistamab, in people with multiple myeloma that has come back or stopped responding to other treatments. The goal is to find the safest and most effective dose and to see how well the drugs shrink tumors.…

This program provides continued treatment with nipocalimab for people with warm autoimmune hemolytic anemia (wAIHA) who have already shown improvement in a previous study. Participants receive the drug by IV infusion every 2 or 4 weeks. The goal is to keep their hemoglobin levels…

This program provides pre-approval access to teclistamab for people with relapsed or refractory multiple myeloma who have no other treatment options left. Participants must have tried and failed all standard therapies, including proteasome inhibitors, IMiDs, and anti-CD38 antibod…

This program provides talquetamab, an experimental drug, to people with multiple myeloma that has returned or not responded to standard treatments. Talquetamab is given as an injection under the skin. The goal is to offer a potential treatment option for patients who have few alt…

This program provides talquetamab, a single-drug treatment, to people with multiple myeloma that has returned or is hard to treat. Participants must have tried all other available therapies and cannot join a clinical trial. The goal is to offer a potential treatment option when n…

This phase 2 study tests whether giving dexamethasone, montelukast, or methotrexate before an amivantamab infusion can reduce or prevent infusion-related reactions in people with a type of advanced lung cancer (EGFR-mutant non-small cell lung cancer). The study enrolled 68 partic…

This study tests an experimental drug called JNJ-89495120 in 107 adults with major depression. The goal is to see if it can reduce depression symptoms faster than a placebo, with checks as early as day 2 and day 5. Participants take the drug alone (no other antidepressants) and a…

This study looks at sleep patterns in 94 adults with major depressive disorder, comparing those with moderate-to-severe insomnia to those with mild or no insomnia. Participants wear a headband at home that records brain activity during sleep and also fill out sleep diaries and qu…

This study collects information from about 889 people with inherited retinal diseases (IRDs) to understand how vision changes over time. Participants have their eyesight and visual field tested regularly. The goal is to learn more about the natural course of these rare eye condit…